DNA Link Inc (127120) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DNA Link Inc (127120) has a cash flow conversion efficiency ratio of -0.060x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-5.37 Billion ≈ $-3.64 Million USD) by net assets (₩89.37 Billion ≈ $60.56 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is DNA Link Inc's balance sheet to measure how much of total assets are equity-financed.
DNA Link Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how DNA Link Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check DNA Link Inc cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
DNA Link Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DNA Link Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Senvest Capital Inc.
TO:SEC
|
0.074x |
|
Anhui Huilong Agricultural Means of Production Co Ltd
SHE:002556
|
0.151x |
|
Hi target Navigation Tech Co
SHE:300177
|
0.010x |
|
Sun International Ltd
JSE:SUI
|
0.548x |
|
Kvutzat Acro Ltd.
TA:ACRO
|
-0.030x |
|
Mitek Systems Inc
NASDAQ:MITK
|
-0.004x |
|
MD Pictures Tbk PT
JK:FILM
|
-0.012x |
|
Energy Absolute Public Company Limited
BK:EA
|
0.034x |
Annual Cash Flow Conversion Efficiency for DNA Link Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of DNA Link Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see DNA Link Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩68.59 Billion ≈ $46.48 Million |
₩-9.39 Billion ≈ $-6.36 Million |
-0.137x | +49.49% |
| 2024-12-31 | ₩25.03 Billion ≈ $16.96 Million |
₩-6.78 Billion ≈ $-4.60 Million |
-0.271x | -41.54% |
| 2023-12-31 | ₩26.28 Billion ≈ $17.81 Million |
₩-5.03 Billion ≈ $-3.41 Million |
-0.191x | -686.44% |
| 2022-12-31 | ₩27.89 Billion ≈ $18.90 Million |
₩910.27 Million ≈ $616.88K |
0.033x | +116.64% |
| 2021-12-31 | ₩32.77 Billion ≈ $22.21 Million |
₩-6.43 Billion ≈ $-4.36 Million |
-0.196x | -993.88% |
| 2020-12-31 | ₩38.70 Billion ≈ $26.23 Million |
₩849.38 Million ≈ $575.62K |
0.022x | +116.32% |
| 2019-12-31 | ₩9.66 Billion ≈ $6.55 Million |
₩-1.30 Billion ≈ $-880.41K |
-0.134x | -64.54% |
| 2018-12-31 | ₩19.60 Billion ≈ $13.29 Million |
₩-1.60 Billion ≈ $-1.09 Million |
-0.082x | +22.37% |
| 2017-12-31 | ₩23.66 Billion ≈ $16.03 Million |
₩-2.49 Billion ≈ $-1.69 Million |
-0.105x | +94.93% |
| 2016-12-31 | ₩1.82 Billion ≈ $1.23 Million |
₩-3.77 Billion ≈ $-2.55 Million |
-2.076x | -523.69% |
| 2015-12-31 | ₩11.20 Billion ≈ $7.59 Million |
₩-3.73 Billion ≈ $-2.53 Million |
-0.333x | -1698.26% |
| 2014-12-31 | ₩7.73 Billion ≈ $5.24 Million |
₩-143.14 Million ≈ $-97.00K |
-0.019x | +58.15% |
| 2012-12-31 | ₩17.70 Billion ≈ $12.00 Million |
₩-783.00 Million ≈ $-530.63K |
-0.044x | +79.15% |
| 2011-12-31 | ₩11.52 Billion ≈ $7.81 Million |
₩-2.44 Billion ≈ $-1.66 Million |
-0.212x | -- |
About DNA Link Inc
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray… Read more